Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: biao luo who wrote (214)	12/16/1997 9:15:00 AM
From: r. peter Dale	Read Replies (1) \| Respond to of 4474

The dimerizing activity of AP1510 was higher than FK1012 in a variety of settings even though its affinity for FKBP was 25-50X lower. This suggests activity towards hFKBP is relatively low. They also indicate they're working on 2nd gen. mols. which binds exclusively to the FKBP fusion protein. Peter Note: The fact that rapamycin is immunosuppressive v/v hFKBP/FRAP as well is acknowledged but not addressed in the JCI paper. They are modifying their constructs to interact with a nonimmunosuppressive rapamycin analogue (successful approach with the cyclosporin-cyclophilin complex).